Hologic Inc Logo

Hologic Inc

HO1.DE

(1.0)
Stock Price

74,50 EUR

28.59% ROA

28.63% ROE

16.16x PER

Market Cap.

0,00 EUR

57.9% DER

0% Yield

26.77% NPM

Hologic Inc Stock Analysis

Hologic Inc Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Hologic Inc Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE falls within an average range (7.03%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

2 ROA

The stock's ROA (7.62%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

3 DER

The stock maintains a fair debt to equity ratio (58%), indicating a reasonable balance between the money it owes and the ownership it possesses.

4 Assets Growth

With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity

5 PBV

The stock's elevated P/BV ratio (3.67x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (-131), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Hologic Inc Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Hologic Inc Technical Stock Analysis
# Analysis Recommendation

Hologic Inc Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Hologic Inc Revenue
Year Revenue Growth
1989 11.400.000
1990 19.800.000 42.42%
1991 17.100.000 -15.79%
1992 26.200.000 34.73%
1993 24.800.000 -5.65%
1994 38.500.000 35.58%
1995 43.400.000 11.29%
1996 88.200.000 50.79%
1997 106.700.000 17.34%
1998 115.600.000 7.7%
1999 84.100.000 -37.46%
2000 93.746.000 10.29%
2001 178.491.000 47.48%
2002 190.192.000 6.15%
2003 204.035.000 6.78%
2004 228.705.000 10.79%
2005 287.684.000 20.5%
2006 462.680.000 37.82%
2007 738.368.000 37.34%
2008 1.674.499.000 55.91%
2009 1.637.134.000 -2.28%
2010 1.679.552.000 2.53%
2011 1.789.349.000 6.14%
2012 2.002.652.000 10.65%
2013 2.492.279.000 19.65%
2014 2.530.700.000 1.52%
2015 2.705.000.000 6.44%
2016 2.832.700.000 4.51%
2017 3.058.800.000 7.39%
2018 3.217.900.000 4.94%
2019 3.367.300.000 4.44%
2020 3.776.400.000 10.83%
2021 5.632.300.000 32.95%
2022 3.813.200.000 -47.71%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Hologic Inc Research and Development Expenses
Year Research and Development Expenses Growth
1989 0
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 3.400.000 100%
1995 4.300.000 20.93%
1996 0 0%
1997 8.500.000 100%
1998 9.800.000 13.27%
1999 12.700.000 22.83%
2000 17.178.000 26.07%
2001 23.328.000 26.36%
2002 20.362.000 -14.57%
2003 18.381.000 -10.78%
2004 16.659.000 -10.34%
2005 18.617.000 10.52%
2006 28.294.000 34.2%
2007 44.484.000 36.4%
2008 81.421.000 45.37%
2009 94.328.000 13.68%
2010 104.305.000 9.57%
2011 116.696.000 10.62%
2012 130.962.000 10.89%
2013 197.646.000 33.74%
2014 203.200.000 2.73%
2015 214.900.000 5.44%
2016 232.100.000 7.41%
2017 232.800.000 0.3%
2018 218.700.000 -6.45%
2019 232.200.000 5.81%
2020 222.500.000 -4.36%
2021 276.300.000 19.47%
2022 304.000.000 9.11%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Hologic Inc General and Administrative Expenses
Year General and Administrative Expenses Growth
1989 5.500.000
1990 7.200.000 23.61%
1991 8.400.000 14.29%
1992 11.400.000 26.32%
1993 13.100.000 12.98%
1994 10.100.000 -29.7%
1995 12.300.000 17.89%
1996 34.800.000 64.66%
1997 28.300.000 -22.97%
1998 39.100.000 27.62%
1999 30.700.000 -27.36%
2000 40.323.000 23.86%
2001 56.274.000 28.35%
2002 47.227.000 -19.16%
2003 52.174.000 9.48%
2004 56.124.000 7.04%
2005 61.777.000 9.15%
2006 98.461.000 37.26%
2007 147.747.000 33.36%
2008 408.929.000 63.87%
2009 148.825.000 -174.77%
2010 159.743.000 6.83%
2011 178.795.000 10.66%
2012 220.042.000 18.75%
2013 227.680.000 3.35%
2014 259.800.000 12.36%
2015 261.000.000 0.46%
2016 267.300.000 2.36%
2017 343.300.000 22.14%
2018 366.100.000 6.23%
2019 332.300.000 -10.17%
2020 356.000.000 6.66%
2021 433.200.000 17.82%
2022 389.200.000 -11.31%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Hologic Inc EBITDA
Year EBITDA Growth
1989 1.800.000
1990 3.900.000 53.85%
1991 1.300.000 -200%
1992 2.400.000 45.83%
1993 -1.700.000 241.18%
1994 4.900.000 134.69%
1995 3.200.000 -53.13%
1996 18.000.000 82.22%
1997 28.800.000 37.5%
1998 18.100.000 -59.12%
1999 -2.300.000 886.96%
2000 -24.599.000 90.65%
2001 -11.946.000 -105.92%
2002 7.226.000 265.32%
2003 10.463.000 30.94%
2004 20.516.000 49%
2005 42.269.000 51.46%
2006 69.356.000 39.06%
2007 179.651.000 61.39%
2008 -106.191.000 269.18%
2009 -1.745.249.000 93.92%
2010 366.884.000 575.7%
2011 646.968.000 43.29%
2012 424.377.000 -52.45%
2013 -395.876.000 207.2%
2014 791.900.000 149.99%
2015 874.100.000 9.4%
2016 1.036.000.000 15.63%
2017 1.832.900.000 43.48%
2018 210.400.000 -771.15%
2019 346.200.000 39.23%
2020 1.499.100.000 76.91%
2021 2.863.400.000 47.65%
2022 1.096.400.000 -161.16%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Hologic Inc Gross Profit
Year Gross Profit Growth
1989 7.300.000
1990 10.600.000 31.13%
1991 8.900.000 -19.1%
1992 13.000.000 31.54%
1993 11.500.000 -13.04%
1994 18.200.000 36.81%
1995 21.900.000 16.89%
1996 47.800.000 54.18%
1997 60.500.000 20.99%
1998 61.600.000 1.79%
1999 37.300.000 -65.15%
2000 34.562.000 -7.92%
2001 62.314.000 44.54%
2002 71.816.000 13.23%
2003 73.580.000 2.4%
2004 85.369.000 13.81%
2005 113.025.000 24.47%
2006 193.532.000 41.6%
2007 345.567.000 44%
2008 892.518.000 61.28%
2009 857.486.000 -4.09%
2010 736.638.000 -16.41%
2011 923.181.000 20.21%
2012 994.437.000 7.17%
2013 1.161.388.000 14.38%
2014 1.245.500.000 6.75%
2015 1.432.700.000 13.07%
2016 1.563.300.000 8.35%
2017 1.621.000.000 3.56%
2018 1.696.700.000 4.46%
2019 1.170.900.000 -44.91%
2020 2.227.500.000 47.43%
2021 3.795.800.000 41.32%
2022 2.058.400.000 -84.41%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Hologic Inc Net Profit
Year Net Profit Growth
1989 1.400.000
1990 2.600.000 46.15%
1991 700.000 -271.43%
1992 1.500.000 53.33%
1993 -1.800.000 183.33%
1994 3.000.000 160%
1995 1.900.000 -57.89%
1996 11.400.000 83.33%
1997 17.700.000 35.59%
1998 10.400.000 -70.19%
1999 -3.700.000 381.08%
2000 -18.619.000 80.13%
2001 -20.850.000 10.7%
2002 179.000 11748.04%
2003 2.882.000 93.79%
2004 12.164.000 76.31%
2005 28.256.000 56.95%
2006 27.423.000 -3.04%
2007 94.578.000 71%
2008 -385.617.000 124.53%
2009 -2.176.237.000 82.28%
2010 -62.813.000 -3364.63%
2011 157.150.000 139.97%
2012 -73.634.000 313.42%
2013 -1.172.838.000 93.72%
2014 17.300.000 6879.41%
2015 131.600.000 86.85%
2016 330.800.000 60.22%
2017 755.500.000 56.21%
2018 -111.300.000 778.8%
2019 -203.600.000 45.33%
2020 1.115.200.000 118.26%
2021 1.871.500.000 40.41%
2022 474.800.000 -294.17%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Hologic Inc Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1989 0
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 1 0%
2008 -2 100%
2009 -8 87.5%
2010 0 0%
2011 1 0%
2012 0 0%
2013 -4 100%
2014 0 0%
2015 0 0%
2016 1 100%
2017 3 50%
2018 0 0%
2019 -1 0%
2020 4 100%
2021 7 42.86%
2022 2 -600%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Hologic Inc Free Cashflow
Year Free Cashflow Growth
1991 -1.600.000
1992 -900.000 -77.78%
1993 -500.000 -80%
1994 -3.500.000 85.71%
1995 700.000 600%
1996 -1.300.000 153.85%
1997 10.500.000 112.38%
1998 -8.000.000 231.25%
1999 -6.600.000 -21.21%
2000 -6.498.000 -1.57%
2001 -14.581.000 55.44%
2002 823.000 1871.69%
2003 -3.415.000 124.1%
2004 18.695.000 118.27%
2005 36.674.000 49.02%
2006 -9.459.000 487.72%
2007 130.410.000 107.25%
2008 311.312.000 58.11%
2009 480.662.000 35.23%
2010 404.232.000 -18.91%
2011 392.018.000 -3.12%
2012 286.949.000 -36.62%
2013 403.692.000 28.92%
2014 428.200.000 5.72%
2015 696.700.000 38.54%
2016 688.700.000 -1.16%
2017 -99.300.000 793.55%
2018 627.300.000 115.83%
2019 535.900.000 -17.06%
2020 740.200.000 27.6%
2021 2.167.700.000 65.85%
2022 137.000.000 -1482.26%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Hologic Inc Operating Cashflow
Year Operating Cashflow Growth
1991 -1.200.000
1992 -400.000 -200%
1993 -300.000 -33.33%
1994 -3.000.000 90%
1995 1.500.000 300%
1996 1.100.000 -36.36%
1997 12.600.000 91.27%
1998 14.600.000 13.7%
1999 2.300.000 -534.78%
2000 -677.000 439.73%
2001 -10.251.000 93.4%
2002 6.961.000 247.26%
2003 4.731.000 -47.14%
2004 25.882.000 81.72%
2005 44.373.000 41.67%
2006 31.124.000 -42.57%
2007 153.250.000 79.69%
2008 364.596.000 57.97%
2009 546.365.000 33.27%
2010 456.712.000 -19.63%
2011 456.024.000 -0.15%
2012 370.222.000 -23.18%
2013 493.822.000 25.03%
2014 508.400.000 2.87%
2015 786.100.000 35.33%
2016 787.200.000 0.14%
2017 8.300.000 -9384.34%
2018 732.900.000 98.87%
2019 649.500.000 -12.84%
2020 896.600.000 27.56%
2021 2.330.400.000 61.53%
2022 168.600.000 -1282.21%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Hologic Inc Capital Expenditure
Year Capital Expenditure Growth
1991 400.000
1992 500.000 20%
1993 200.000 -150%
1994 500.000 60%
1995 800.000 37.5%
1996 2.400.000 66.67%
1997 2.100.000 -14.29%
1998 22.600.000 90.71%
1999 8.900.000 -153.93%
2000 5.821.000 -52.89%
2001 4.330.000 -34.43%
2002 6.138.000 29.46%
2003 8.146.000 24.65%
2004 7.187.000 -13.34%
2005 7.699.000 6.65%
2006 40.583.000 81.03%
2007 22.840.000 -77.68%
2008 53.284.000 57.14%
2009 65.703.000 18.9%
2010 52.480.000 -25.2%
2011 64.006.000 18.01%
2012 83.273.000 23.14%
2013 90.130.000 7.61%
2014 80.200.000 -12.38%
2015 89.400.000 10.29%
2016 98.500.000 9.24%
2017 107.600.000 8.46%
2018 105.600.000 -1.89%
2019 113.600.000 7.04%
2020 156.400.000 27.37%
2021 162.700.000 3.87%
2022 31.600.000 -414.87%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Hologic Inc Equity
Year Equity Growth
1989 100.000
1990 15.700.000 99.36%
1991 16.700.000 5.99%
1992 18.100.000 7.73%
1993 16.300.000 -11.04%
1994 19.900.000 18.09%
1995 22.700.000 12.33%
1996 107.300.000 78.84%
1997 126.800.000 15.38%
1998 140.400.000 9.69%
1999 150.400.000 6.65%
2000 131.572.000 -14.31%
2001 111.807.000 -17.68%
2002 142.409.000 21.49%
2003 148.927.000 4.38%
2004 166.275.000 10.43%
2005 217.834.000 23.67%
2006 605.750.000 64.04%
2007 805.723.000 24.82%
2008 4.642.269.000 82.64%
2009 2.512.715.000 -84.75%
2010 2.698.549.000 6.89%
2011 2.936.895.000 8.12%
2012 2.961.031.000 0.82%
2013 1.941.513.000 -52.51%
2014 2.063.000.000 5.89%
2015 2.079.200.000 0.78%
2016 2.142.700.000 2.96%
2017 2.784.700.000 23.05%
2018 2.428.800.000 -14.65%
2019 2.115.700.000 -14.8%
2020 2.705.200.000 21.79%
2021 4.218.600.000 35.87%
2022 4.876.200.000 13.49%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Hologic Inc Assets
Year Assets Growth
1989 5.400.000
1990 20.300.000 73.4%
1991 19.800.000 -2.53%
1992 22.700.000 12.78%
1993 22.200.000 -2.25%
1994 28.500.000 22.11%
1995 33.900.000 15.93%
1996 123.100.000 72.46%
1997 144.700.000 14.93%
1998 172.600.000 16.16%
1999 175.800.000 1.82%
2000 219.655.000 19.97%
2001 195.119.000 -12.57%
2002 184.275.000 -5.88%
2003 188.603.000 2.29%
2004 211.751.000 10.93%
2005 279.839.000 24.33%
2006 856.205.000 67.32%
2007 1.066.349.000 19.71%
2008 8.134.632.000 86.89%
2009 5.689.828.000 -42.97%
2010 5.625.834.000 -1.14%
2011 6.008.780.000 6.37%
2012 10.477.108.000 42.65%
2013 9.000.823.000 -16.4%
2014 8.414.700.000 -6.97%
2015 7.670.100.000 -9.71%
2016 7.317.000.000 -4.83%
2017 7.979.600.000 8.3%
2018 7.230.900.000 -10.35%
2019 6.442.100.000 -12.24%
2020 7.195.800.000 10.47%
2021 8.919.900.000 19.33%
2022 9.071.200.000 1.67%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Hologic Inc Liabilities
Year Liabilities Growth
1989 5.300.000
1990 4.600.000 -15.22%
1991 3.100.000 -48.39%
1992 4.600.000 32.61%
1993 5.900.000 22.03%
1994 8.600.000 31.4%
1995 11.200.000 23.21%
1996 15.800.000 29.11%
1997 17.900.000 11.73%
1998 32.200.000 44.41%
1999 25.400.000 -26.77%
2000 88.083.000 71.16%
2001 83.312.000 -5.73%
2002 41.866.000 -99%
2003 39.676.000 -5.52%
2004 45.476.000 12.75%
2005 62.005.000 26.66%
2006 250.455.000 75.24%
2007 260.626.000 3.9%
2008 3.492.363.000 92.54%
2009 3.177.113.000 -9.92%
2010 2.927.285.000 -8.53%
2011 3.071.885.000 4.71%
2012 7.516.077.000 59.13%
2013 7.059.310.000 -6.47%
2014 6.351.700.000 -11.14%
2015 5.590.900.000 -13.61%
2016 5.174.300.000 -8.05%
2017 5.194.900.000 0.4%
2018 4.802.100.000 -8.18%
2019 4.326.400.000 -11%
2020 4.488.500.000 3.61%
2021 4.701.300.000 4.53%
2022 4.195.000.000 -12.07%

Hologic Inc Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
18.51
Net Income per Share
4.96
Price to Earning Ratio
16.16x
Price To Sales Ratio
0x
POCF Ratio
9.9
PFCF Ratio
0
Price to Book Ratio
4.31
EV to Sales
0.1
EV Over EBITDA
0.23
EV to Operating CashFlow
0.23
EV to FreeCashFlow
0.24
Earnings Yield
0.06
FreeCashFlow Yield
0
Market Cap
0,00 Bil.
Enterprise Value
0,48 Bil.
Graham Number
45.49
Graham NetNet
-4.11

Income Statement Metrics

Net Income per Share
4.96
Income Quality
1.63
ROE
0.29
Return On Assets
0.14
Return On Capital Employed
0.21
Net Income per EBT
0.82
EBT Per Ebit
0.94
Ebit per Revenue
0.35
Effective Tax Rate
0.18

Margins

Sales, General, & Administrative to Revenue
0.08
Research & Developement to Revenue
0.06
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.62
Operating Profit Margin
0.35
Pretax Profit Margin
0.33
Net Profit Margin
0.27

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
8.09
Free CashFlow per Share
7.61
Capex to Operating CashFlow
-0.06
Capex to Revenue
-0.03
Capex to Depreciation
-0.3
Return on Invested Capital
0.18
Return on Tangible Assets
0.29
Days Sales Outstanding
46.36
Days Payables Outstanding
0
Days of Inventory on Hand
122.04
Receivables Turnover
7.87
Payables Turnover
0
Inventory Turnover
2.99
Capex per Share
-0.48

Balance Sheet

Cash per Share
8,90
Book Value per Share
18,56
Tangible Book Value per Share
18.56
Shareholders Equity per Share
18.56
Interest Debt per Share
11.11
Debt to Equity
0.58
Debt to Assets
0.31
Net Debt to EBITDA
0.23
Current Ratio
4.12
Tangible Asset Value
0,36 Bil.
Net Current Asset Value
-0,33 Bil.
Invested Capital
0.58
Working Capital
2,92 Bil.
Intangibles to Total Assets
0.5
Average Receivables
0,78 Bil.
Average Payables
0,00 Bil.
Average Inventory
562450000
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Hologic Inc Dividends
Year Dividends Growth

Hologic Inc Profile

About Hologic Inc

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. The company is headquartered in Marlborough, Massachusetts and currently employs 6,478 full-time employees. The firm operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. The company offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.

CEO
Mr. Stephen MacMillan
Employee
6.478
Address
250 Campus Dr
Marlborough,

Hologic Inc Executives & BODs

Hologic Inc Executives & BODs
# Name Age

Hologic Inc Competitors